Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Silencing the eye

Silencing the eye

RNAi-mediated gene silencing of angiogenic factors involved in pathologic neovascularization has been shown to work in vivo for the first time, as researchers reported last week that they used RNA

Read the full 342 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE